Before targeted therapies like trastuzumab, patients with HER2-positive lung cancer had limited options apart from standard chemotherapy, with generally poor outcomes and greater side effects.

HER2-positive metastatic breast cancer, an aggressive disease characterized by overexpression or amplification of HER2, occurs in approximately 15% to 20% of patients with metastatic breast cancer.

There were no cases of HER2 positivity among patients with gliomas, sarcomas, small cell lung cancer, gastrointestinal stromal tumors, thyroid carcinoma, uterine sarcoma, thymic carcinoma, and Merkel ...

A new study led by investigators from Mass General Brigham trialed stereotactic (targeted) brain-directed radiation in 100 ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this ...